Company Profiles

driven by the PitchBook Platform

Solace Therapeutics

Solace Therapeutics
1997 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series C LATEST DEAL TYPE
$13M LATEST DEAL AMOUNT
4 INVESTORS
Description

Developer of non-surgical, office-based treatments for common bladder disorders. The company focuses on treatment of female stress urinary incontinence and overactive bladder (OAB).

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Services
Primary Office
  • 135 Newbury Street
  • Framingham, MA 01701
  • United States

+1 (508) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Solace Therapeutics’s full profile, request a free trial.

Solace Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 06-Sep-2016 $13M 0000 000.00 Completed Product Development
3. Later Stage VC (Series B) 31-Dec-2013 0000 0000 000.00 Completed Product Development
2. Early Stage VC (Series B2) 13-Jul-2006 $3M $3M 000.00 Completed Startup
1. Early Stage VC (Series A) Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Solace Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A 20,978,417 $0.001000 8% $0.5 $0.5 1x $0.5 21.05%
To view this company’s complete Cap Table, request access »

Solace Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
Boston Scientific Corporation Minority 000 0000 000000 0
Spray Venture Partners Venture Capital Minority 000 0000 000000 0
Saints Capital Secondary Buyer Minority 000 0000 000000 0

Solace Therapeutics Executive Team (4)

Name Title Board
Seat
Contact
Info
William Gruber President, Chief Executive Officer & Board Member
Lisa Gruttadauria Controller
Nicole Shugrue Vice President, Marketing
Albert Chin Vice President, Research & Development

Solace Therapeutics Board Members (6)

Name Representing Role Since Contact
Info
Ali Behbahani MD New Enterprise Associates Board Member 000 0000
John McDonough Self Board Member 000 0000
Kevin Connors Spray Venture Partners Board Member 000 0000
Ryan Drant New Enterprise Associates Board Member 000 0000
Stacy Seng Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »